Treatment of unresectable hepatic hilar malignancies with self-expanding metallic stents

Hepatogastroenterology. 1999 Sep-Oct;46(29):2781-90.

Abstract

Background/aims: This study assesses the treatment of biliary obstruction in patients with hilar malignancies by metallic stents.

Methodology: Twenty-one consecutive patients with unresectable malignant biliary obstruction at the hepatic hilum (Bismuth type II, III and IV) were treated with percutaneous transhepatic placement of self-expandable metallic endoprostheses. The endoprostheses were successfully inserted in all patients. In 12 patients all segments of the liver were drained and in 9 patients partial segments of the liver were drained.

Results: Seventeen patients (81%) showed relief from jaundice and could be freed of external drainage tubes. Ten patients (48%) showed no recurrent symptoms due to stent obstruction until death. Overall survival was 4.86+/-4.15 (mean+/-SD) months, stent patency was 3.76+/-3.64 months and comfort index representing a ratio of well-being was 70.5+/-38.3%. There was no significant difference in survival rate, stent patency or comfort index between the groups with complete and those with partial drainage.

Conclusions: Even in patients with complicated hepatic hilar biliary occlusions, internal drainage using metallic stents can relieve jaundice and leave patients free of external tubes with a comfortable quality of life.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Bile Duct Neoplasms / diagnostic imaging
  • Bile Duct Neoplasms / mortality
  • Bile Duct Neoplasms / secondary
  • Bile Duct Neoplasms / therapy*
  • Cholangiography
  • Cholestasis, Intrahepatic / diagnostic imaging
  • Cholestasis, Intrahepatic / mortality
  • Cholestasis, Intrahepatic / therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Quality of Life
  • Stents*
  • Survival Rate